Scientists Identify a Potential Treatment Candidate for Early Type 2 Diabetic Retinopathy (IMAGE)

Elsevier

Scientists Identify a Potential Treatment Candidate for Early Type 2 Diabetic Retinopathy

Caption

Relative mRNA expression levels of thioredoxin-interacting protein (TXNIP) (A), and glial fibrillary acidic protein (GFAP) (B) based on the average expression levels of the nondiabetic mice group (db/dm) (set as 1.0); P=0.047. C: TXNIP and GFAP assessment by Western blotting (top panel), statistical analysis of relative optic density of TXNIP (bottom left panel) and GFAP (bottom right panel) to beta-actin among the groups based on the Western blot immunoreactive bands in the neurosensory retina. Data are expressed as means ± SEM. n=5 db/dm. n=7 D-CON, INS, and LIX. *P < 0.05, ***P < 0.001. db/dm, nondiabetic mice; D-CON, untreated diabetic mice; INS, diabetic mice treated with insulin; LIX, diabetic mice treated with lixisenatide; qPCR, quantitative PCR.

Credit

The American Journal of Pathology

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.